Maravai Lifesciences Holdings Inc Revenue Growth Rates (MRVI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Maravai Lifesciences Holdings Inc   (NASDAQ: MRVI)
 

MRVI's Revenue Growth by Quarter and Year

Maravai Lifesciences Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MRVI/growth
https://api.csimarket.com/api/v1/companies/MRVI/fundamentals
https://api.csimarket.com/api/v1/companies/MRVI/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
MRVI Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 45.85
2nd Quarter June 51.44
1st Quarter March 65.70
FY 162.99

MRVIs Annual Revenue
Maravai Lifesciences Holdings Inc 's Revenue in the fiscal year 2025 $ 184.99 millions
Maravai Lifesciences Holdings Inc 's Revenue in the fiscal year 2024 $ 259.19 millions
Maravai Lifesciences Holdings Inc 's Revenue in the fiscal year 2023 $ 288.95 millions
Maravai Lifesciences Holdings Inc 's Revenue in the fiscal year 2022 $ 883.00 millions
Maravai Lifesciences Holdings Inc 's Revenue in the fiscal year 2021 $ 799.24 millions




MRVI Revenue third quarter 2026 Y/Y Growth Comment
Maravai Lifesciences Holdings Inc reported Revenue increase of 12.77% year on year in the third quarter 2026, to $ 45.85 millions, this is lower than Maravai Lifesciences Holdings Inc 's recent average Revenue improvement of 23.2%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 108 other companies have achieved higher Revenue growth. While Maravai Lifesciences Holdings Inc ' s Revenue growth of 12.77% ranks overall at the positon no. 1890 in the third quarter 2026.


MRVI Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 12.77 %
2nd Quarter June 8.52 %
1st Quarter March 40.23 %
FY   -

Financial Statements
Maravai Lifesciences Holdings Inc 's third quarter 2026 Revenue $ 45.85 millions MRVI's Income Statement
Maravai Lifesciences Holdings Inc 's third quarter 2025 Revenue $ 40.66 millions Quarterly MRVI's Income Statement


MRVI Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -10.87 %
2nd Quarter June -21.7 %
1st Quarter March 31.16 %
FY (Year on Year)   -


Back to MRVI Growth rate Comparisons >> Back to MRVI Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #109
Healthcare Sector #289
Overall #1890

Revenue Y/Y Growth Statistics
High Average Low
364.29 % 23.2 % -71.61 %
(Dec 31 2022)   (Mar 31 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #109
Healthcare Sector #289
Overall #1890
Revenue Y/Y Growth Statistics
High Average Low
364.29 % 23.2 % -71.61 %
(Dec 31 2022)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Maravai Lifesciences Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
87.31 % 3.97 % -61.4 %
(Sep 30 2020)  


MRVI's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Maravai Lifesciences Holdings Inc disclosed drop in Revenue from the second quarter by -10.87% to $ 45.85 millions, from $ 51.44 millions achived in the previous reporting period.

But that's not important problem, as Maravai Lifesciences Holdings Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 159 other companies have achieved higher Revenue quarter on quarter growth. While Maravai Lifesciences Holdings Inc 's Revenue growth quarter on quarter, overall rank is 3288.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #160
Healthcare Sector #455
Overall #3288
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #160
Healthcare Sector #455
Overall #3288
Revenue Q/Q Growth Statistics
High Average Low
87.31 % 3.97 % -61.4 %
(Sep 30 2020)  


MRVI's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Maravai Lifesciences Holdings Inc disclosed drop in Revenue from the second quarter by -10.87% to $ 45.85 millions, from $ 51.44 millions achived in the previous reporting period.

But that's not important problem, as Maravai Lifesciences Holdings Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 159 other companies have achieved higher Revenue quarter on quarter growth. While Maravai Lifesciences Holdings Inc 's Revenue growth quarter on quarter, overall rank is 3288.


Maravai Lifesciences Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 207.89
Y / Y Revenue Growth (TTM) -3.69 %
Year on Year Revenue Growth Overall Ranking # 3262
Seqeuential Revenue Change (TTM) 1.98 %
Seq. Revenue Growth (TTM) Overall Ranking # 3051


Cumulative Revenue growth Comment
Maravai Lifesciences Holdings Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Maravai Lifesciences Holdings Inc 's annual Revenue improvement would be -3.69% year on year to $208 millions.

In the Healthcare sector 445 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2125 to 3262.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 134
Healthcare Sector # 446
Overall # 3262

Revenue TTM Y/Y Growth Statistics
High Average Low
10.48 %
 -31.16 %
-68.41 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 134
Sector # 412
S&P 500 # 3051
Cumulative Revenue growth Comment
Maravai Lifesciences Holdings Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Maravai Lifesciences Holdings Inc 's annual Revenue drop would be -3.69% year on year to $208 millions.

In the Healthcare sector 445 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2125 to 3262.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 134
Healthcare Sector # 446
Overall # 3262

Revenue TTM Y/Y Growth Statistics
High Average Low
10.48 %
-31.16 %
-68.41 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 134
Sector # 412
S&P 500 # 3051




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MRVI's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Outset Medical Inc 17.51%$ 17.510 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions


About Maravai Lifesciences Holdings Inc Revenue Growth Rates (MRVI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Maravai Lifesciences Holdings Inc (CIK 1823239).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001823239-26-000068
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Maravai Lifesciences Holdings Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.